Viking Therapeutics Reports New Data from VK2735 Obesity …
Nov 4, 2024 · Mild nausea was reported in 23 (32%) VK2735-treated subjects compared with 11% among placebo subjects. No moderate or severe nausea was reported. Vomiting was reported in three (4%) VK2735-treated subjects. Diarrhea was reported in five subjects (7%) receiving VK2735 compared with four subjects (21%) receiving placebo.
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study …
1 day ago · News provided by Viking Therapeutics, Inc. Nov 12, 2024, 16:05 ET . Share this article ... Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1 ...
Viking Therapeutics to Highlight Clinical Data from VK2735 …
Oct 28, 2024 · VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic...
News & Events - Viking Therapeutics InvestorRoom
Feb 27, 2024 · Data from a Phase 1 and a Phase 2a trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. The company is also evaluating an oral formulation of VK2735 in a Phase 1 trial.
Viking Therapeutics Announces Positive Top-Line Results from …
Feb 27, 2024 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
ObesityWeek 2024: Viking Therapeutics Presents New Positive …
Nov 4, 2024 · New clinical trial data regarding Viking Therapeutics' VK2735, an investigational dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, will be highlighted at ObesityWeek 2024, being held November 3-6 …
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study …
1 day ago · Latest News. Stock Market. Originals. The Morning Brief. Premium News. Economics. Housing. Earnings. Tech. ... Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like ...
Viking Therapeutics' Obesity Drug Data Shows Promising Early …
RTTNews. Nov. 4, 2024, 12:49 AM. (RTTNews) - Viking Therapeutics Inc. (VKTX) on Sunday issued positive early results in the trial of its experimental obesity pill VK2735, reports said, citing a ...
Viking Therapeutics Reports New Data from VK2735 Obesity …
Nov 4, 2024 · Poster Presentation #017: First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults. Poster #017 presented updated data from the previously reported 28-day ...
VK2735 - Viking Therapeutics
VK2735 demonstrated encouraging safety and tolerability following 13 weeks of once-weekly dosing in the Phase 2 VENTURE study. Discontinuation rates were low and well-balanced among patients treated with VK2735 compared with placebo.